Perioperative FLOT vs Adjuvant XELOX for CA Stomach

This is a single centre randomised controlled trial, comparing perioperative FLOT versus adjuvant XELOX for locally advanced gastric and esophagogastric junction cancers. Patients with operable clinical T3 or above and N1 or above gastric and esophagastric junction cancer would be recruited. Participants would be randomised to perioperative FLOT versus adjuvant XELOX with curative radical gastrectomy. Primary outcome would be 3 year Disease Free Survival. It was calculated that 110 patients would be required to demonstrate the study hypothesis.

Trial Details

NCT ID
NCT05264896
Phase
PHASE3
Sponsor
Chinese University of Hong Kong
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • 5-FU, Leucovorin, Oxaliplatin, Docetaxel
  • XELOX
Locations (sample)
  • Hong Kong, Hong Kong|22.27832,114.17469

Key Eligibility Criteria

  • Locally advanced adenocarcinoma of stomach or esophagogastric junction (Siewert type II and III), defined by clinical stage ≥T3 and/or ≥N1, in the …
  • Surgically resectable disease based on clinical staging
  • No previous gastrectomy or chemotherapy
  • Age 18 or above but less than 80, and

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →